NEW YORK (Reuters) - Antibody levels are a good predictor of how effective Moderna Inc's COVID-19 vaccine is, according to a new study released on Tuesday, a finding which could help speed up future clinical trials for vaccines against the disease.
Regulators currently rely on large placebo-controlled studies to determine if a vaccine works, but the study medrxiv.org/content/10.1101..., conducted by scientists from the Fred Hutchinson Cancer Research Center, the National Institute of Allergy and Infectious Diseases, Moderna and elsewhere, showed that measuring the antibody levels in vaccine recipients could also determine effectiveness.